Sironax Tech Stack

Clinical-stage biotech developing therapies for neurodegeneration, inflammation, and metabolic disease

Biotechnology Waltham, Massachusetts 51–200 employees Founded 2017 Privately Held

Sironax is a clinical-stage biotech with three programs in human trials (SARM1, NAMPT, RIPK1 inhibitors) targeting aging-related pathology across neurodegeneration, inflammatory, and metabolic indications. The tech stack—GROMACS, Python, R, TensorFlow, PyTorch, AWS, and in silico modeling—reveals a computational-first drug discovery operation, with active projects in AI/ML target prediction and antibody brain-delivery platforms. Leadership hiring (VPs, directors, Chief of Staff) and accelerating research recruitment signal a scaled transition from discovery into clinical development.

Tech Stack 10 technologies

Core StackPython TensorFlow PyTorch AWS GROMACS R Perl GCP Phoenix CDISC

What Sironax Is Building

◆Challenges

Crossing blood-brain barrier
Developing multi-modal conjugates
Managing complex antibody programs
Enhancing drug design efficiency
Analyzing large-scale omics data
Accelerating drug discovery
Complex adme challenges
Budget forecasting and accruals
Risk mitigation
Ensuring trial quality and data integrity

▲Active Projects

Antibody-based brain delivery platform development
First-in-human studies
Dose-ranging studies
Multi-modal conjugates
Ind-enabling translation
Integration of in vitro and in vivo pharmacology strategies
Establishment and validation of innovative in vitro and in vivo models for cns disorders
Preparation of pharmacology sections for ind applications
In silico drug design platform
Ai/ml model development for target prediction

Hiring Activity

Accelerating15 roles · 7 in 30d

Department

Research

Healthcare

Data

Executive

Seniority

Director

Senior

Lead

Notable leadership hires: Biologics Director, Chief of Staff, Clinical pharmacology Director, Clinical pharmacology director

Company intelligence

Find more companies like Sironax by tech stack, pain points and active projects

Get started free

About Sironax

Sironax, founded in 2017 and based in Waltham, Massachusetts, develops small-molecule and antibody therapies targeting contributors of aging and degeneration. The company is in active clinical development: SIR2501 (SARM1 inhibitor), SIR4156 (NAMPT activator), and SIR9900 (RIPK1 inhibitor) are enrolled in first-in-human and dose-ranging studies. The pipeline spans neurodegenerative, inflammatory, immunological, metabolic, and rare-disease indications. Operating footprint includes hiring across the United States, China, Australia, and the United Kingdom. The organization carries research-heavy operations (7 open roles in research) alongside clinical pharmacology and data functions.

HeadquartersWaltham, Massachusetts

Company Size51–200 employees

Founded2017

Hiring MarketsChina, United States, Australia, United Kingdom

Frequently Asked Questions

What is Sironax's clinical pipeline?

Three programs in human trials: SIR2501 (SARM1 inhibitor), SIR4156 (NAMPT activator), and SIR9900 (RIPK1 inhibitor). Ongoing first-in-human and dose-ranging studies across neurodegenerative, inflammatory, and metabolic indications.

What tech stack does Sironax use for drug discovery?

GROMACS, Python, R, Perl, TensorFlow, PyTorch, AWS, GCP, Phoenix, and CDISC. Stack reflects computational chemistry and machine-learning integration into target prediction and in silico drug design workflows.